Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Immunology·MeSH: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Prevalence
30.0 / 100K
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis?
There are 1 clinical trial targeting Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis tracked by BioSniper.
What is the prevalence of Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis?
The estimated prevalence of Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis is approximately 30.0 per 100,000 population.
Deep-dive into Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis